Patient characteristics and acute cardiovascular event rates among patients with very high-risk and non-very high-risk atherosclerotic cardiovascular disease

被引:6
作者
Fonarow, Gregg C. [1 ]
Kosiborod, Mikhail N. [2 ,3 ]
Rane, Pallavi B. [4 ]
Nunna, Sasikiran [5 ]
Villa, Guillermo [6 ]
Habib, Mohdhar [4 ]
Arellano, Jorge [4 ]
Mues, Katherine E. [4 ]
Sun, Kainan [5 ]
Wade, Rolin L. [5 ]
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Ahmanson UCLA Cardiomyopathy Ctr, Los Angeles, CA 90095 USA
[2] St Lukes Mid Amer Heart Inst, Kansas City, MO USA
[3] Univ Missouri, Kansas City, MO 64110 USA
[4] Amgen Inc, Thousand Oaks, CA 91320 USA
[5] IQVIA, Plymouth Meeting, PA USA
[6] Amgen Europe GmbH, Zug, Switzerland
关键词
atherosclerotic cardiovascular disease; major cardiovascular events; real-world evidence; very high-risk; CHOLESTEROL; METAANALYSIS; THERAPY;
D O I
10.1002/clc.23706
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The risk for subsequent major cardiovascular (CV) events among patients with very high-risk (VHR) atherosclerotic CV disease (ASCVD) remains to be fully elucidated. Hypothesis We assessed the characteristics and major CV event rates of patients with VHR versus non-VHR ASCVD in a real-world setting in the United States (US), hypothesizing that patients with VHR ASCVD would have higher CV event rates. Methods This was a retrospective cohort study conducted from January 01, 2011, to June 30, 2018, in the US using the Prognos LDL-C database linked to the IQVIA PharMetrics Plus (R) database supplemented with the IQVIA prescription claims (Dx/LRx) databases. Patients were >= 18 years old and had >= 2 non-ancillary medical claims in the linked databases at least 30 days apart. The study was conducted in 2 stages: (1) identification of patients with ASCVD who met the definition of VHR ASCVD and a matched cohort of non-VHR ASCVD patients using the incidence density sampling (IDS) approach; (2) estimation of the occurrence of major CV events. Results Among patients with >= 1 major ASCVD event (N=147,679), most qualified as VHR ASCVD (79.5%). There were 115,460 patients each in IDS-matched VHR and non-VHR ASCVD cohorts. The composite myocardial infarction/ischemic stroke event rates in the VHR and non-VHR ASCVD cohorts were 8.04 (95% confidence interval [95% CI]: 7.87-8.22) and 0.82 (95% CI: 0.77-0.88) events per 100 patient-years, respectively, during the 1-year post-index period. Conclusions Most patients with >= 1 previous major ASCVD event treated in real-world US clinical practice qualified as VHR ASCVD. Patients with VHR ASCVD had much higher rates of major CV events versus non-VHR ASCVD patients.
引用
收藏
页码:1457 / 1466
页数:10
相关论文
共 26 条
[1]  
[Anonymous], 2014, EGEMS WASH DC
[2]   Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials [J].
Baigent, C. ;
Blackwell, L. ;
Emberson, J. ;
Holland, L. E. ;
Reith, C. ;
Bhala, N. ;
Peto, R. ;
Barnes, E. H. ;
Keech, A. ;
Simes, J. ;
Collins, R. .
LANCET, 2010, 376 (9753) :1670-1681
[3]   Demographic And Clinical Characteristics Of Patients Prescribed Proprotein Convertase Subtilisin/kexin Type 9 Inhibitor Therapy And Patients Whose Current Lipid-Lowering Therapy Was Modified [J].
Baum, Seth J. ;
Wade, Rolin L. ;
Xiang, Pin ;
Arellano, Jorge ;
Olmos, Cesar Cerezo ;
Nunna, Sasikiran ;
Chen, Chi-Chang ;
Carter, Cathryn M. ;
Desai, Nihar R. .
THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2019, 15 :1325-1332
[4]   Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events A Meta-Analysis of Statin Trials [J].
Boekholdt, S. Matthijs ;
Hovingh, G. Kees ;
Mora, Samia ;
Arsenault, Benoit J. ;
Amarenco, Pierre ;
Pedersen, Terje R. ;
LaRosa, John C. ;
Waters, David D. ;
DeMicco, David A. ;
Simes, R. John ;
Keech, Antony C. ;
Colquhoun, David ;
Hitman, Graham A. ;
Betteridge, John ;
Clearfield, Michael B. ;
Downs, John R. ;
Colhoun, Helen M. ;
Gotto, Antonio M., Jr. ;
Ridker, Paul M. ;
Grundy, Scott M. ;
Kastelein, John J. P. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 64 (05) :485-494
[5]   Getting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): Methods and baseline data of a registry of high cardiovascular risk patients in the United States [J].
Cannon, Christopher P. ;
de Lemos, James A. ;
Rosenson, Robert S. ;
Ballantyne, Christie M. ;
Liu, Yuyin ;
Yazdi, Daniel ;
Elliott-Davey, Mary ;
Mues, Katherine E. ;
Bhatt, Deepak L. ;
Kosiborod, Mikhail N. .
AMERICAN HEART JOURNAL, 2020, 219 :70-77
[6]   Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes [J].
Cannon, Christopher P. ;
Blazing, Michael A. ;
Giugliano, Robert P. ;
McCagg, Amy ;
White, Jennifer A. ;
Theroux, Pierre ;
Darius, Harald ;
Lewis, Basil S. ;
Ophuis, Ton Oude ;
Jukema, J. Wouter ;
De Ferrari, Gaetano M. ;
Ruzyllo, Witold ;
De Lucca, Paul ;
Im, KyungAh ;
Bohula, Erin A. ;
Reist, Craig ;
Wiviott, Stephen D. ;
Tershakovec, Andrew M. ;
Musliner, Thomas A. ;
Braunwald, Eugene ;
Califf, Robert M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (25) :2387-2397
[7]   Ischemic Event Rates in Very-High-Risk Adults [J].
Colantonio, Lisandro D. ;
Shannon, Erin D. ;
Orroth, Kate K. ;
Zaha, Rebecca ;
Jackson, Elizabeth A. ;
Rosenson, Robert S. ;
Exter, Jason ;
Mues, Katherine E. ;
Muntner, Paul .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 74 (20) :2496-2507
[8]   Adherence to High-Intensity Statins Following a Myocardial Infarction Hospitalization Among Medicare Beneficiaries [J].
Colantonio, Lisandro D. ;
Huang, Lei ;
Monda, Keri L. ;
Bittner, Vera ;
Serban, Maria-Corina ;
Taylor, Benjamin ;
Brown, Todd M. ;
Glasser, Stephen P. ;
Muntner, Paul ;
Rosenson, Robert S. .
JAMA CARDIOLOGY, 2017, 2 (08) :890-895
[9]   Isotretinoin and Risk for Inflammatory Bowel Disease A Nested Case-Control Study and Meta-analysis of Published and Unpublished Data [J].
Etminan, Mahyar ;
Bird, Steven T. ;
Delaney, Joseph A. ;
Bressler, Brian ;
Brophy, James M. .
JAMA DERMATOLOGY, 2013, 149 (02) :216-220
[10]   Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel [J].
Ference, Brian A. ;
Ginsberg, Henry N. ;
Graham, Ian ;
Ray, Kausik K. ;
Packard, Chris J. ;
Bruckert, Eric ;
Hegele, Robert A. ;
Krauss, Ronald M. ;
Raal, Frederick J. ;
Schunkert, Heribert ;
Watts, Gerald F. ;
Boren, Jan ;
Fazio, Sergio ;
Horton, Jay D. ;
Masana, Luis ;
Nicholls, Stephen J. ;
Nordestgaard, Borge G. ;
van de Sluis, Bart ;
Taskinen, Marja-Riitta ;
Tokgozoglu, Lale ;
Landmesser, Ulf ;
Laufs, Ulrich ;
Wiklund, Olov ;
Stock, Jane K. ;
Chapman, M. John ;
Catapano, Alberico L. .
EUROPEAN HEART JOURNAL, 2017, 38 (32) :2459-2472